EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Transcriptional CDKs 7, 8, and 9 with Anilinopyrimidine Derivatives as Anticancer Agents: Design, Synthesis, Biological Evaluation and In Silico Studies

Razan Eskandrani, Lamees S Al-Rasheed, Siddique Akber Ansari iD, Ahmed H Bakheit iD, Abdulrahman A Almehizia iD, Maha Almutairi iD, Hamad M Alkahtani iD

Molecules · 2023

DOI: 10.3390/molecules28114271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Razan Eskandrani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinases (CDKs) are promising targets in chemotherapy. In this study, we report a series of 2-anilinopyrimidine derivatives with CDK inhibitory activity. Twenty-one compounds were synthesized and their CDK inhibitory and cytotoxic activities were evaluated. The representative compounds demonstrate potent antiproliferative activities toward different solid cancer cell lines and provide a promising strategy for the treatment of malignant tumors. Compound 5f was the most potent CDK7 inhibitor (IC50 = 0.479 µM), compound 5d was the most potent CDK8 inhibitor (IC50 = 0.716 µM), and compound 5b was the most potent CDK9 inhibitor (IC50 = 0.059 µM). All the compounds satisfied the Lipinski’s rule of five (molecular weight < 500 Da, number of hydrogen bond acceptors

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansMolecular StructureStructure-Activity RelationshipLigandsMolecular Docking SimulationCyclin-Dependent KinasesCell ProliferationDrug Screening Assays, AntitumorDrug DesignCell Line, Tumor

Stichwörter der Autor:innen

2-anilinopyrimidineCDKantiproliferative activitymolecular docking

Substanzen

LigandsAntineoplastic AgentsCyclin-Dependent Kinases

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
  • Drug Exploration and Development (DEDC), Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.

ORCID-Profile: Siddique Akber Ansari, Ahmed H Bakheit, Abdulrahman A Almehizia, Maha Almutairi, Hamad M Alkahtani

Förderung

  • Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia

Zitieren

APA

Eskandrani, R., Al-Rasheed, L. S., Ansari, S. A., Bakheit, A. H., Almehizia, A. A., Almutairi, M., & Alkahtani, H. M. (2023). Targeting Transcriptional CDKs 7, 8, and 9 with Anilinopyrimidine Derivatives as Anticancer Agents: Design, Synthesis, Biological Evaluation and In Silico Studies. Molecules. https://doi.org/10.3390/molecules28114271

Vancouver

Eskandrani R, Al-Rasheed LS, Ansari SA, Bakheit AH, Almehizia AA, Almutairi M, et al. Targeting Transcriptional CDKs 7, 8, and 9 with Anilinopyrimidine Derivatives as Anticancer Agents: Design, Synthesis, Biological Evaluation and In Silico Studies. Molecules. 2023. doi:10.3390/molecules28114271

BibTeX
@article{Eskandrani2023,
  author = {Eskandrani, Razan and Al-Rasheed, Lamees S and Ansari, Siddique Akber and Bakheit, Ahmed H and Almehizia, Abdulrahman A and Almutairi, Maha and Alkahtani, Hamad M},
  title = {Targeting Transcriptional CDKs 7, 8, and 9 with Anilinopyrimidine Derivatives as Anticancer Agents: Design, Synthesis, Biological Evaluation and In Silico Studies},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28114271}
}
Kostenlos starten →